Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials  by unknown
Articles
Introduction
In early breast cancer, surgery can remove any disease
that has been detected in or around the breast or
regional lymph nodes, but undetected deposits of
disease may remain either locally (ie, in the residual
breast tissue, scar area, chest wall, or regional lymph
nodes) or at distant sites that could, if untreated,
develop into life-threatening recurrence. Many
randomised trials over the past half century have
studied the effects of radiotherapy and of the extent of
surgery on local disease control and on cause-speciﬁc
mortality in early breast cancer. This report updates
previous meta-analyses1–4 of the individual patient data
from those trials.
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Summary
Background In early breast cancer, variations in local treatment that substantially affect the risk of locoregional
recurrence could also affect long-term breast cancer mortality. To examine this relationship, collaborative meta-
analyses were undertaken, based on individual patient data, of the relevant randomised trials that began by 1995.
Methods Information was available on 42 000 women in 78 randomised treatment comparisons (radiotherapy vs no
radiotherapy, 23 500; more vs less surgery, 9300; more surgery vs radiotherapy, 9300). 24 types of local treatment
comparison were identiﬁed. To help relate the effect on local (ie, locoregional) recurrence to that on breast cancer
mortality, these were grouped according to whether or not the 5-year local recurrence risk exceeded 10% (10%,
17 000 women; 10%, 25 000 women). 
Findings About three-quarters of the eventual local recurrence risk occurred during the ﬁrst 5 years. In the
comparisons that involved little (10%) difference in 5-year local recurrence risk there was little difference in 
15-year breast cancer mortality. Among the 25 000 women in the comparisons that involved substantial (10%)
differences, however, 5-year local recurrence risks were 7% active versus 26% control (absolute reduction 19%), and
15-year breast cancer mortality risks were 44·6% versus 49·5% (absolute reduction 5·0%, SE 0·8, 2p0·00001). 
These 25 000 women included 7300 with breast-conserving surgery (BCS) in trials of radiotherapy (generally just to
the conserved breast), with 5-year local recurrence risks (mainly in the conserved breast, as most had axillary
clearance and node-negative disease) 7% versus 26% (reduction 19%), and 15-year breast cancer mortality risks
30·5% versus 35·9% (reduction 5·4%, SE 1·7, 2p=0·0002; overall mortality reduction 5·3%, SE 1·8, 2p=0·005).
They also included 8500 with mastectomy, axillary clearance, and node-positive disease in trials of radiotherapy
(generally to the chest wall and regional lymph nodes), with similar absolute gains from radiotherapy; 5-year local
recurrence risks (mainly at these sites) 6% versus 23% (reduction 17%), and 15-year breast cancer mortality risks
54·7% versus 60·1% (reduction 5·4%, SE 1·3, 2p=0·0002; overall mortality reduction 4·4%, SE 1·2, 2p=0·0009).
Radiotherapy produced similar proportional reductions in local recurrence in all women (irrespective of age or
tumour characteristics) and in all major trials of radiotherapy versus not (recent or older; with or without systemic
therapy), so large absolute reductions in local recurrence were seen only if the control risk was large. 
To help assess the life-threatening side-effects of radiotherapy, the trials of radiotherapy versus not were combined
with those of radiotherapy versus more surgery. There was, at least with some of the older radiotherapy regimens, a
signiﬁcant excess incidence of contralateral breast cancer (rate ratio 1·18, SE 0·06, 2p=0·002) and a signiﬁcant
excess of non-breast-cancer mortality in irradiated women (rate ratio 1·12, SE 0·04, 2p=0·001). Both were slight
during the ﬁrst 5 years, but continued after year 15. The excess mortality was mainly from heart disease (rate ratio
1·27, SE 0·07, 2p=0·0001) and lung cancer (rate ratio 1·78, SE 0·22, 2p=0·0004). 
Interpretation In these trials, avoidance of a local recurrence in the conserved breast after BCS and avoidance of a
local recurrence elsewhere (eg, the chest wall or regional nodes) after mastectomy were of comparable relevance to
15-year breast cancer mortality. Differences in local treatment that substantially affect local recurrence rates would,
in the hypothetical absence of any other causes of death, avoid about one breast cancer death over the next 15 years
for every four local recurrences avoided, and should reduce 15-year overall mortality.
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Post-BCS radiotherapy
After breast-conserving surgery (BCS), a particularly
common site of local recurrence is the conserved breast
itself (or the axilla, if this has not been treated
effectively). The risk of recurrence in a conserved breast
can be substantial even in node-negative disease that has
been conﬁrmed by axillary clearance, and it can be
greatly reduced by radiotherapy.4,5 Hence, the recent
National Institutes of Health (NIH) consensus
conference on early breast cancer6 recommended that
after BCS there should be radiotherapy to the conserved
breast. Recent surveys in North America and Europe
indicate that this treatment is generally given.7 It is,
however, not always given,8 since later recurrence in a
conserved breast can usually be removed by further
surgery. Breast radiotherapy immediately after BCS
could improve long-term survival (by comparison with a
policy of watchful waiting for any local recurrence) only
if life-threatening spread from tumour cells in the
conserved breast would otherwise occur after BCS but
before any clinically evident local recurrence was
detected and treated, or if the local disease could then
not be controlled adequately. Hence, radiotherapy is
likely to have little effect on early mortality, whatever
effect it might have on long-term breast cancer
mortality.
Post-mastectomy radiotherapy
Even after mastectomy, an appreciable risk of local
recurrence (eg, in the chest wall or lymph nodes) can
remain unless some reliable method of investigation,
such as axillary clearance, has found no evidence of
nodal involvement. If axillary investigation reveals nodal
involvement (or if the axilla has not been adequately
investigated), post-mastectomy radiotherapy can produce
a substantial absolute reduction in this risk of local
recurrence, and previous trials9–12 and meta-analyses2–4
have shown that although it has little effect on breast
cancer mortality during the ﬁrst few years, it can produce
a moderate, but deﬁnite, reduction in longer-term breast
cancer mortality. Hence, the NIH consensus conference6
recommended radiotherapy after mastectomy for women
at high risk of locoregional recurrence (eg, those with four
or more involved lymph nodes).
Long-term follow-up of mortality
Moderate differences in mortality that take many years
to emerge can best be assessed by systematic meta-
analyses of the data on every individual patient in all
relevant randomised trials. Even this method of
assessment, however, will yield reliable answers only if
large numbers of relevant individuals have been
randomised and followed up for many years. Our
previous reviews of individual patient data included
follow-up of the surgery trials only to 19903 and follow-up
of the radiotherapy trials4 only to 1995. In the latter
review,4 the effect on long-term breast cancer mortality
was only marginally signiﬁcant in the trials of post-BCS
radiotherapy, although more clearly signiﬁcant in those
of post-mastectomy radiotherapy. Moreover, in the data
then available, all-cause mortality was not signiﬁcantly
reduced by radiotherapy after either BCS or mastectomy.
More recently, a review of just the published results
from the post-BCS radiotherapy trials found only a
marginally signiﬁcant difference in all-cause mortality,
but noted that an updated meta-analysis of individual
patient data would be more reliable.13
The present review of individual patient data from ran-
domised trials of local treatments involves substantially
longer follow-up than our previous reviews.3,4 For the
post-BCS radiotherapy trials in particular, many of which
started relatively recently, and for at least the most recent
post-mastectomy radiotherapy trials, this longer follow-
up should offer a much more reliable assessment of the
long-term effects on mortality. The main results for these
two particular comparisons are presented separately,
before the more general analyses that bring together data
from all the local treatment comparisons.
The main aim of this report is to assess quantitatively
the relationship between local control and long-term
breast cancer mortality. It deals only semi-quantitatively
with the effects of some radiotherapy regimens on
mortality several years later from other conditions (eg,
heart disease and lung cancer14–16), and does not
investigate the extent to which the long-term fatal (or non-
fatal) adverse effects of local treatment can be avoided by
the substantial changes that have taken place over the past
few decades in radiotherapy and surgery techniques.17–19
Methods
Every 5 years since 1985 evidence from the randomised
trials in early breast cancer has been reviewed centrally,
in a worldwide collaboration between the individuals
now responsible for them (as the Early Breast Cancer
Trialists’ Collaborative Group, EBCTCG). An EBCTCG
report published earlier this year20 gave the results up to
the year 2000 from the trials that began by 1995 of
systemic treatments (chemotherapy or hormonal
therapy) for early breast cancer. The present report gives
the corresponding results from the trials of local
treatments (various types of surgery or radiotherapy, or
both), using similar methods.
Treatment comparisons and main outcomes 
Information was available (table 1) from several trials of
post-BCS radiotherapy (mostly to the conserved breast);
of post-mastectomy radiotherapy (mostly to the chest
wall and locoregional lymph nodes, after axillary
clearance); of more surgery versus less surgery in the
absence of radiotherapy; of more surgery versus less
surgery in the presence of radiotherapy; and of surgery
versus radiotherapy (ie, more surgery versus less surgery
plus additional radiotherapy). Only unconfounded trials
were considered (ie, trials in which there was to be no
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difference between the treatment groups in the use of
systemic therapy). No speciﬁc studies of the relevance of
newer diagnostic techniques, such as sentinel lymph
node biopsy,21 were available. Webtables 1–3 give brief
design details of each of the available treatment
comparisons in the three main parts of table 1.
For all unconfounded randomised trials that began
recruitment by 1995, information was sought for every
patient on her initial characteristics, allocated
treatment, and time to various outcomes. These
outcomes were: breast cancer recurrence; whether the
ﬁrst such recurrence was a distant or an isolated local
recurrence (ie, an ipsilateral locoregional recurrence
occurring before any contralateral or other distant
recurrence); cause-speciﬁc and overall mortality; and
the incidence of second primary cancers before breast
cancer recurrence.
Data management procedures
Trial identiﬁcation and data handling procedures were
as in the EBCTCG report on systemic therapies,20 except
that: (i) more detail was sought of the surgical
procedures, radiotherapy regimens, and deﬁnitions of
local recurrence (from protocols, publications, or
correspondence; see webtables 1–3); (ii) breast cancer in
the contralateral breast was not counted as local
recurrence; (iii) more detail was sought (by correspon-
dence) about the underlying causes of many of the
deaths, particularly from circulatory disease, lung
cancer, or uncertain causes, before any recurrence of
breast cancer; and (iv) more deﬁnite information was
sought (by correspondence) if it was unclear whether the
ﬁrst recurrence was just an isolated local recurrence. 
In treatment comparisons where the extent of axillary
surgery was identical in both groups, classiﬁcation of
axillary nodal status as positive or negative was based on
pathological information where available, and on clinical
information where not. The few women with unknown
nodal status were combined with those with clinically
node-positive disease. In treatment comparisons where
the extent of axillary surgery differed between the groups
(eg, axillary surgery vs axillary radiotherapy), classiﬁ-
cation of nodal status was based only on clinical
information, to avoid bias. 
For every randomised treatment comparison, local
recurrence was deﬁned in the same way for both groups.
In the trials of radiotherapy versus not, this generally
included recurrence (or a new breast cancer) in the
residual breast tissue, scar area, chest wall, or ipsilateral
regional lymph nodes, and in the trials involving
surgery, trial-speciﬁc local recurrence deﬁnitions are
given in webtables 2 and 3. Where recurrences just in a
conserved breast or axilla had not originally been
reported to the collaboration, information on them was
sought, and they are now included as local recurrences. 
Statistical analysis
All analyses were stratiﬁed by trial, by time since
randomisation in single years, and by nodal status
(negative or positive). The main analyses of local
recurrence, breast cancer mortality, and overall mortality
were also stratiﬁed by age in 5 groups (40, 40–49, 50–59,
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Treatments compared Available for analysis* Not yet available†
Trials Deaths Women Trials Women
RT versus no RT, but the same surgery
BCS, generally with AC, then RT versus no RT‡ 10 1940 7311 3 1150
MastectomyAC, then RT versus no RT 25 6265 9933 2 165
MastectomyAS, then RT versus no RT 4 360 647 0 0
Mastectomy alone, then RT versus no RT 7 3890 5597 0 0
More surgery versus less surgery, but the same (or no) RT
IMC removal versus not, both with mastectomy and no RT 2 793 1082 0 0
Pectoral muscle removal versus not, both with mastectomy (mainly CAMS China trial) 4 1347 4925 2 ~200
AC versus not in node-positive disease, both with mastectomy and some RT 2 240 266 5 ~552
AC versus not in node-negative disease, both with mastectomy and no axillary RT 4 757 1154 0 0
MastectomyAC versus BCSAC, neither with RT (part of NSABP B-06 trial) 1 660 1432 0 0
MastectomyAC versus BCSAC, both with RT 2 185 428 0 0
BCS with more versus less breast surgery, neither with AC 0 0 0 3 ~216
More surgery (active) versus less surgery plus RT (control)
Nodal surgery versus RT 9 2910 4550 1 ~100
MastectomyAC versus BCSRT (Guy’s Hospital trial) 1 509 630 0 0
Mastectomy versus BCSRT, both with AC 7 1675 4125 3 ~540
Total* 78 21 531 42 080 19 ~2923 (6%)
RT=radiotherapy. AC=axillary clearance. AS=axillary sampling. IMC=internal mammary chain of lymph nodes. *Some trials (eg, NSABP B-06: about 700 mastectomyACRT vs about
700 mastectomyAC vs about 700 BCSAC) contribute to more than one type of treatment comparison, so their control group might be counted more than once in the total. Without
such double counting, the total would be 70 trials available, with 19 291 deaths among 38 047 women (93% of total). †Numbers of trials known to be unavailable: in such studies,
numbers randomised are by year 2000, and might be uncertain (or wholly unavailable, in which case they are taken as 100, since such studies might well be small). ‡In eight trials  of post-
BCS RT all women were to have AC, but in two (85B Scottish and 85D West Midlands) only some were to do so. In most trials of post-BCS RT, irradiation was generally just to the breast,
but in some the irradiated sites included axilla, supraclavicular fossa, and internal mammary chain (AFIMC).
Table 1: Availability of data from unconfounded randomised trials of local therapy that began by 1995
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60–69, 70 years at randomisation). Only two groups
(50 and 50 years) were used, however, for analyses
that were further subdivided by tumour characteristics
(grade, size, oestrogen-receptor [ER] status, or actual
number of involved nodes). Other aspects of the statistical
methods and the formats of the ﬁgures are as before,20
unless otherwise indicated, and are described on the
EBCTCG website (see panel).
In early breast cancer, most local recurrences become
apparent within the ﬁrst few years, but much of the distant
recurrence and breast cancer mortality occurs later.4 The
main analyses involve 5-year local recurrence risks and 15-
year breast cancer mortality risks. Both are generally
illustrated by 15-year graphs (for comparability with the
EBCTCG report20 on systemic therapies), but the logrank
observed minus expected (O–E) values that yield the
signiﬁcance tests associated with such graphs are based
on events throughout the entire period of follow-up, both
during and after the ﬁrst 15 years, unless otherwise
indicated. For the major treatment comparisons, results
for overall mortality (“any death”) are also given, mainly
on the website. 
Collaborative review
Preliminary meta-analyses of the trials of local
treatments had been presented and discussed at a
meeting of collaborators in September, 2000, after which
much additional detail was sought about methods and
outcomes in these trials, and restructured, corrected
meta-analyses emerged in 2004. A draft of the present
report was circulated for comment by the collaborating
trialists in June, 2005, was presented and discussed at a
further meeting of collaborators in September, 2005,
and was available for further comment in October, 2005.
It was revised substantially in the light of these
comments and recirculated when submitted for
publication in November, 2005 (and, during the editorial
process page proofs were posted on the password-
protected EBCTCG website).
Role of the funding sources
This collaboration is funded from the general long-term
ﬁnancial support of the CTSU by organisations that had
no role in study design, data collection, data analysis, data
interpretation, or writing of the report. The EBCTCG
secretariat had full access to all the data and analyses and,
after consultation with the collaborators, had ﬁnal
responsibility for the decision to submit for publication.
Results
Table 1 shows the numbers of trials and the numbers of
randomised women who contributed to various local
treatment comparisons. The two most extensively studied
aspects of local treatment are radiotherapy after BCS (7311
women in 10 trials) and radiotherapy after mastectomy
and axillary clearance (9933 women in 25 trials). The
results (subdivided by nodal status, thereby making four
separate treatment comparisons) for these two particular
sets of trials are presented ﬁrst. Then information from all
the treatment comparisons in table 1 (again subdivided by
nodal status, making a total of 24 comparisons) is used to
relate the magnitude of the effect on local recurrence to
that on breast cancer mortality. Finally, the effects of the
radiotherapy regimens in these trials on the incidence of
second cancers and on mortality from diseases other than
breast cancer are presented.
Radiotherapy after BCS
Figure 1 gives, for the ten trials of post-BCS radiotherapy,
logrank analyses of the effects on local recurrence (upper
part of ﬁgure) and on breast cancer mortality (lower part).
Separate subtotals are given (a) for trials in which the
conserved breast was the only site irradiated (sometimes
with an additional boost to the scar) and (b) for those
where other sites were also irradiated, such as the axilla
and supraclavicular fossa. One of the ten trials contributed
to both subtotals, so there are 11 strata in ﬁgure 1. The
reduction in local recurrence (mainly in the conserved
breast) produced by allocation to radiotherapy is
substantial and highly signiﬁcant (p0·00001) in every
separate trial. There is no signiﬁcant heterogeneity
between the proportional reductions in local recurrence in
the 11 different strata in ﬁgure 1, or in the two subtotals.
The recurrence rate ratio, comparing those allocated
radiotherapy with those not, is about 0·3 in every trial,
corresponding to a proportional reduction of 70%.
Considering all ten trials together, the 5-year risk of local
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Panel: Webtables 1–4 and webﬁgures 1–10 on the Lancet
website
Webtables 1–3 provide brief details of every available trial
(including the anatomic sites treated surgically and the
radiotherapy doses and sites irradiated), and webtable 4 shows
how the statistics for breast cancer mortality are derived by
logrank subtraction (ie, subtraction of the logrank statistics for
mortality from causes other than breast cancer from the logrank
statistics for any death). The 15-year time-to-event graphs in
webﬁgures 1–3 provide more detail for some of the main meta-
analyses (including the logrank statistics for local recurrence,
breast cancer mortality, and any death during years 0–4, 5–9,
10–14, and 15), webﬁgures 4 and 5 relate the effect on local
recurrence to the proportional effect on breast cancer mortality,
and webﬁgure 6 gives various subgroup analyses. Webﬁgure 7
(radiotherapy side-effects) gives 15-year time-to-event graphs
for the incidence of contralateral breast cancer and for mortality
from causes other than breast cancer. Finally, the forest plots in
webﬁgures 8–10 give summary results for every separate trial
(separating women with node-negative and node-positive
disease) for local recurrence, breast cancer mortality, and any
death. This report and the webtables and webﬁgures are also
available on the EBCTCG website (www.ctsu.ox.ac.uk/projects/
ebctcg), along with Powerpoint images of some of them.
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Year started
and study name
RT
sites
    Deaths/women
Allocated
BCSRT
                 Ratio of annual death rates
                 BCSRT : BCS
Logrank
O–E
Variance
of O–E
     BCSRT deaths
(a) Radiotherapy only to conserved breast: 14% node positive
NSABP B-06 BW* 267/731 305/7191976 135·019·7
Uppsala-Örebro BW 37/184 34/1971981 16·82·3
St George’s London BW* 24/128 25/1221982 10·92·5
Ontario COG BW+S 91/416 123/4211984 51·516·4
INT Milan 3 BW+S* 40/294 51/2731987 21·36·2
NSABP B-21 BWS* 8/337 8/3361989 3·90·5
Swedish BCCG BW 32/593 41/5941991 18·03·9
499/
2683
587/
2662
45·8 257·4
0·84 (SE 0·06),
2p=0·004
  (a) Subtotal
(b) Radiotherapy to conserved breast and other sites: 24% node positive
St George’s London BWAF* 31/80 28/701982 12·22·1
Scottish BWS(AF)IMC  59/293 78/2961985 30·25·0
West Midlands, UK BWSAFIMC 88/358 107/3491985 45·311·4
CRC, UK Various 76/259 89/2611986 37·68·3
254/
990
302/
976
26·9 125·3
0·81 (SE 0·08),
2p=0·02
  (b) Subtotal
753/
3673
889/
3638
72·7 382·7
0·83 (SE 0·05),
2p=0·0002
  Total (ab)
Allocated
BCS
Breast cancer mortality (deaths/women)
0 0·5 1·0 1·5 2·0
BCS+RT better BCS+RT worse
Year started
and study name
RT
sites
    Events/woman-years
Allocated
BCSRT
Ratio of annual event rates
BCSRT : BCS
Logrank
O–E
Variance
of O–E
     BCSRT events
(a) Radiotherapy only to conserved breast: 14% node positive
NSABP B-06 BW* 125/6862 285/49911976 84·893·3
Uppsala-Örebro BW 10/1636 43/15111981 12·717·7
St George’s London BW* 12/1202 31/10471982 9·611·5
Ontario COG BWS 53/3543 155/27541984 48·258·2
INT Milan 3 BWS* 19/2478 60/20051987 18·225·1
NSABP B-21 BWS* 6/1810 40/17291989 11·217·3
Swedish BCCG BW 33/3718 92/34291991 30·530·8
258/
21 249
706/
17 466
7·2% 25·6%
7·7% 26·7%
254·0 215·3
0·31 (SE 0·04),
2p0·00001
  (a) Subtotal
5-year risk
5-year risk
7·3% 25·9%5-year risk
28·0% 33·2%15-year risk
28·2% 35·1%10-year risk
30·5% 35·9%15-year risk
(b) Radiotherapy to conserved breast and other sites: 24% node positive
St George’s London BWAF* 14/620 30/3801982 9·710·9
Scottish BWS(AF)IMC 16/2598 83/22601985 22·533·0
West Midlands, UK BWSAFIMC 42/2398 104/19291985 34·236·8
CRC, UK Various 33/1604 77/14541986 25·724·3
105/
7220
294/
6023
105·0 92·1
0·32 (SE 0·06),
2p0·00001
  (b) Subtotal
363/
28 469
1000/
23 489
359·0 307·4
0·31 (SE 0·03),
2p0·00001
  Total (ab)
Allocated
BCS
Isolated local recurrence (events/woman-years)
0 0·5 1·0 1·5 2·0
BCS+RT better BCS+RT worse
Heterogeneity between 11 strata: 2 10=3·8; p=0·96
Heterogeneity between 11 strata: 2 10=7·8; p=0·6
Figure 1: Effect of
radiotherapy (RT) after
BCS (ten trials) on local
recurrence and on breast
cancer mortality—
event rate ratios
O–E=observed–expected.
BW=breast/chest wall.
S=scar (as site of RT boost).
AF=axilla/fossa. 
IMC=internal mammary chain.
Sites in parentheses not always
treated.
*Some systemic adjuvant
therapy (same
polychemotherapy and/or
tamoxifen) in both groups.
99% CIs are given for trial-
speciﬁc results (black squares)
and 95% CIs are given for
subtotals and totals
(white diamonds).
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recurrence is 7% among those allocated radiotherapy and
26% among those not, corresponding to an absolute
reduction of 19% in this 5-year risk.
The proportional risk reduction for breast cancer
mortality is much less extreme than that for local
recurrence, and none of the trial-speciﬁc breast cancer
mortality results is clearly signiﬁcant on its own (as each
of the 99% CIs overlaps unity). The total result at the
bottom of ﬁgure 1 is, however, highly signiﬁcant (breast
cancer death rate ratio 0·83, SE 0·05, 95% CI 0·75–0·91,
2p=0·0002), indicating a reduction of about one-sixth in
the annual breast cancer mortality rate. The 15-year risk of
death from breast cancer (in the hypothetical absence of
other causes) is 30·5% among those allocated post-BCS
radiotherapy and 35·9% among those not (corresponding
to an absolute reduction of 5·4%, SE 1·7). The similarity
of the subtotals (a) and (b) in the upper part of ﬁgure 1 is
because all of the effect in (a), and much of that in (b), is
from irradiating the conserved breast, and the clear
reduction in breast cancer mortality given in the total
(ab) at the foot of ﬁgure 1 shows the effectiveness of
breast irradiation in these patients. 
The total results in ﬁgure 1 for local recurrence and for
breast cancer mortality are plotted in ﬁgure 2 by year
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5-year gain 16·1% (SE 1·0)
5-year gain 30·1% (SE 2·8)
15-year gain 5·1% (SE 1·9)
Logrank 2p=0·006
15-year gain 7·1% (SE 3·6)
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Figure 2: Effect of radiotherapy (RT) after BCS on local recurrence and on breast cancer mortality—15-year probabilities
Data from 10 trials. Vertical lines indicate 1 SE above or below the 5, 10, and 15 year percentages. 
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since randomisation, separating node-negative and
node-positive disease. The 5-year risk of local recurrence
is substantially bigger in node-positive disease, as is the
absolute reduction in this recurrence risk (ie, the 5-year
gain: ﬁgure 2). The absolute reduction in breast cancer
mortality also appears somewhat larger for women with
node-positive disease, but the numbers are too small for
this ﬁnding to be statistically reliable.
Radiotherapy after mastectomy and axillary clearance
Figure 3 gives the corresponding results for women with
axillary clearance in the trials of post-mastectomy
radiotherapy. In the majority of these trials radiotherapy
was given to the chest wall and to the lymph nodes in the
axilla, supraclavicular fossa, and internal mammary
chain (webtable 1, webﬁgure 8). 
For women with node-negative disease, the 5-year
local recurrence risk after mastectomy and axillary
clearance was only 6% even in the absence of radio-
therapy. Although radiotherapy reduces it to
2% (2p=0·0002), the absolute 5-year gain is only 4% and
there is no signiﬁcant reduction in 15-year breast cancer
mortality (indeed, there appears if anything to be a
slight increase, but the numbers of events are small). 
By contrast, for women with node-positive disease the
5-year local recurrence risk after mastectomy and axillary
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5-year gain 4·0% (SE 1·1)
5-year gain 17·1% (SE 0·9)
15-year loss 3·6% (SE 2·6)
Logrank 2p=0·01
(excluding data beyond year 15: logrank 2p=0·18)
15-year gain 5·4% (SE 1·3)
Logrank 2p=0·0002
MastectomyACRT
6·3
2·3
8·0
3·1
MastectomyAC 
31·3% 
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Figure 3: Effect of radiotherapy (RT) after mastectomy and axillary clearance (AC) on local recurrence and on breast cancer mortality—15-year probabilities
Data from 25 trials. Vertical lines indicate 1 SE above or below the 5, 10, and 15 year percentages.
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clearance is 23% in the absence of radiotherapy, which is
substantial, and radiotherapy reduces it to 6%.
Therefore, although the proportional reduction in the
local recurrence rate produced by radiotherapy is similar
in node-positive disease and in node-negative disease,
the absolute 5-year gain is much larger (17%). In node-
positive disease the 15-year breast cancer mortality with
and without post-mastectomy radiotherapy is 54·7%
versus 60·1%, an absolute reduction of 5·4% (SE 1·3,
2p=0·0002).
This analysis of the effects of post-mastectomy
radiotherapy in node-positive disease is limited to the
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Type of local treatment
comparison
Isolated local recurrences (events): cumulative risk by year 5 after randomisation
Events by year 5/
women randomised*
Active Control
5-year risk
(actuarial %)
Active Control
Absolute reduction in 5-year
risk (%), control–active
Reduction (SE) Reduction (99% CI)
RT versus no RT, but same surgery
BCS then RT versus no RT (10 trials)
Node-negative 216/3071 637/3026 6·7 22·9 16·1% (1·0)
Node-positive 66/602 221/612 11·0 41·1 30·1% (2·8)
MastectomyAC then RT versus no RT (25 trials)
Node-negative 13/662 41/691 2·3 6·3 4·0% (1·1)
Node-positive 214/4170 778/4170 5·8 22·8 17·1% (0·9)
MastectomyAS then RT versus no RT (4 trials)
Node-negative 13/225 52/224 6·1 24·5 18·5% (3·5)
Node-positive 11/95 43/103 13·8 50·1 36·3% (7·5)
Mastectomy alone then RT versus no RT (7 trials)
Node-negative 70/1427 307/1477 5·6 23·3 17·6% (1·4)
Node-positive 88/837 243/836 11·6 33·5 21·9% (2·3)
More surgery versus less surgery, but the same (or no) RT
IMC removal versus not, neither with RT (2 trials)
Node-negative 11/243 9/251 4·7 4·0 0·7% (1·9)
Node-positive 42/286 50/302 19·1 21·3 2·2% (4·0)
Pectoral muscle removal versus not, both with same RT or no RT (4 trials)
Node-negative 1/49 2/56 2·2 4·1 1·8% (3·5)
Node-positive 59/330 60/309 22·2 22·9 0·8% (3·8)
AC versus not, in node-positive disease, both with some RT (2 trials)
Node-positive 7/129 13/137 7·5 13·5 6·1% (4·6)
AC versus not, in node-negative disease, neither with axillary RT (4 trials)
Node-negative 51/572 119/582 11·9 23·0 11·1% (2·5)
MastectomyAC versus BCSAC, neither with RT (part of NSABP B-06)
Node-negative 46/432 149/432 10·9 36·5 25·6% (3·3)
Node-positive 46/281 128/287 18·9 52·1 33·1% (5·0)
MastectomyAC versus BCSAC, both with RT (2 trials)
Node-negative 2/59 4/60 5·7 5·2  0·5% (4·6)
Node-positive 5/153 10/156 4·2 8·0 3·9% (3·1)
More surgery (active) versus less surgery plus RT (control)
Nodal surgery versus RT (9 trials)
Node-negative 123/1343 113/1329 10·8 9·6 1·2% (1·3)
Node-positive 221/943 170/935 27·6 21·8 5·8% (2·3)
MastectomyAC versus BCS aloneRT (Guy’s Hospital)
Node-negative 15/241 52/233 6·4 25·3 18·9% (3·7)
Node-positive 11/85 22/71 15·8 35·5 19·6% (8·8)
Mastectomy versus BCSRT, both with AC (7 trials)
Node-negative 71/1432 115/1438 5·3 8·6 3·3% (1·0)
Node-positive 40/610 26/645 7·9 4·7 3·1% (1·5)
+30 +20 +10 0
Active better
Figure 4: Absolute reduction in 5-year local recurrence risk—78 randomised comparisons  grouped into 24 types of local treatment comparison, based on treatments compared and nodal status
RT=radiotherapy. AC=axillary clearance. AS=axillary sampling. IMC=internal mammary chain of lymph nodes. 
*A few trials did not provide data on local recurrence, so in some comparisons numbers differ from table 1.
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8500 women who had had axillary clearance. Its ﬁndings
for local recurrence and for breast cancer mortality
would not have been materially altered, however, by
inclusion of the additional 2500 women who had
had only axillary sampling, or no axillary surgery
(webﬁgure 8b). In every large trial of post-mastectomy
radiotherapy in women with node-positive disease there
was a similar proportional reduction in local recurrence,
showing that the radiotherapy regimens used in all the
main trials, recent or older, were of comparable efﬁcacy
in achieving local control (webﬁgure 8b). Hence, when
assessing the relevance of local control to long-term
breast cancer mortality, it is appropriate to consider the
evidence from both recent and older trials. 
Comparison of post-BCS and post-mastectomy
radiotherapy trials
In the post-BCS radiotherapy trials, the site of local
recurrence was generally available. When it was, over
90% (578 of 636) of the local recurrences among controls
involved the conserved breast, as did over 90% of the
effect of radiotherapy on local recurrence. In the post-
mastectomy radiotherapy trials, the site of local
recurrence was not generally available. However, little
breast tissue remains after mastectomy, so the main
effect of radiotherapy on local recurrence in these post-
mastectomy trials must involve other sites, such as the
chest wall or regional lymph nodes.
Coincidentally, the 5-year risks of local recurrence
without radiotherapy, and the reduction in those risks
produced by radiotherapy, were similar among women
with node-negative disease in the post-BCS trials and
among women with node-positive disease in the post-
mastectomy trials (ﬁgure 2, upper panels, and ﬁgure 3,
lower panels). The control 15-year breast cancer
mortality was, of course, lower among women in the
post-BCS trials (about 80% of whom had small tumours
[greatest dimension 20 mm] and node-negative
disease) than among women in the post-mastectomy
trials with node-positive disease. For both, however, it
was substantial, and for both the absolute reduction in
breast cancer mortality with radiotherapy was about 5%.
The apparent similarity of the absolute reductions in 
15-year breast cancer mortality in these two types of
radiotherapy trial after similar absolute reductions in 
5-year local recurrence risk suggests that the effect on
long-term survival of avoiding a recurrence in a
conserved breast is approximately comparable with that
of avoiding a recurrence at other locoregional sites. 
Three categories of local treatment comparison
To examine the general relationship between the effects
of local treatment differences on local recurrence and
their effects on breast cancer mortality, all the treatment
comparisons listed in table 1 were subdivided by nodal
status, making a total of 24 such comparisons. These were
then grouped arbitrarily into three categories according to
the absolute reduction (10%, 10–20%, or 20%) in the
5-year local recurrence risk. The 24 white squares and
their 99% CIs in ﬁgure 4 display these absolute reductions
in risk. (The length of the side of each white square is
inversely proportional to the standard error of the
absolute reduction.) The vertical broken lines correspond
to absolute reductions of 10% and 20% in risk, and have
been used as arbitrary cut-points to group these 24 types
of comparison into three categories, according to the
absolute reduction in this risk. These categories involve,
respectively, 17 000, 20 000, and 5000 women, with mean
absolute reductions of 1%, 17%, and 26% in the 5-year
local recurrence risk.
Most of the substantial absolute reductions in local
recurrence risk involved the addition of radiotherapy.
(The others involved conservation of the breast or axilla
[or both] without effective radiotherapy to the conserved
tissue.) Furthermore, almost all the comparisons of
radiotherapy versus no radiotherapy involved substantial
absolute reductions in local recurrence; the one exception
was that after mastectomy and axillary clearance in
women with pathologically node-negative disease, the
risk of local recurrence without radiotherapy was so low
that no large absolute reduction was possible (ﬁgures 3
and 4). In the lower part of ﬁgure 4 the four earliest trials
(those starting during 1951–1970: webﬁgure 10) had high
local recurrence risks despite radiotherapy. Omission of
these early trials from subsequent analyses would make
no material difference to the main conclusions.
Local control and long-term breast cancer mortality
The absolute reductions in breast cancer mortality that
correspond to the three categories of local treatment
comparison are shown in table 2. The differences in
breast cancer mortality are greater at 15 years than at
5 years, and the 15-year differences in breast cancer
mortality in the three categories are approximately
proportional to the differences in 5-year local recurrence
risk. The regression line through zero, relating the
absolute effects on local recurrence to those on breast
cancer mortality, suggests that a local treatment
difference that reduces the 5-year local recurrence risk
by 20% would reduce the 15-year breast cancer mortality
by 5·2% (SE 0·8, 2p0·00001). 
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Breast cancer mortality (%)
5-year risk 5-year absolute 15-year risk 15-year absolute 
(active vs control) reduction (SE) (active vs control) reduction (SE)
(a) 10% (mean 1%) 18·8 vs 19·5 0·6 (0·6) 41·3 vs 42·3 1·0 (0·9)
(b) 10–20% (mean 17%) 21·8 vs 23·3 1·5 (0·6) 44·0 vs 48·5 4·5 (0·8)
(c) 20% (mean 26%) 24·9 vs 26·7 1·8 (1·3) 47·4 vs 53·4 6·0 (1·6)
Subtotal (bc) (mean 19%) 22·4 vs 24·0 1·6 (0·6) 44·6 vs 49·5 5·0 (0·8)
Weighted regression line through zero, relating mortality reduction to recurrence reduction: 5·2%, SE 0·8, absolute reduction in
15-year breast cancer mortality for 20% absolute reduction in 5-year local recurrence risk.
Table 2: Breast cancer mortality risks by time since randomisation and by category of absolute reduction
in 5-year local recurrence risk (from ﬁgure 4)
Articles
A quantitatively similar conclusion can be obtained by
combining the second and third categories (b and c in
table 2), and analysing the resulting total of 25 000
women.  Among them, treatment reduced the 5-year
local recurrence risk by a mean of 19% and reduced the
15-year breast cancer mortality by 5·0% (SE 0·8,
2p0·00001).  The ﬁndings for these 25 000 women are
plotted against time since randomisation in ﬁgure 5
(lower panels). The effect on local recurrence is
substantial, and is seen rapidly;  indeed, much of it is
apparent within the ﬁrst two or three years.  In contrast,
there is no apparent effect on breast cancer mortality
within the ﬁrst two or three years, although there is a
moderate but deﬁnite effect on 15-year breast cancer
mortality.  Most of these 25 000 women were in trials of
radiotherapy and half had node-negative disease, so the
results for them are intermediate between those for post-
BCS radiotherapy in node-negative disease (ﬁgure 2,
upper panels) and post-mastectomy radiotherapy in
node-positive disease (ﬁgure 3, lower panels).
Further details of these comparisons are given on the
website (webtable 4, webﬁgures 3–6). For the treatment
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Figure 5: Local recurrence and breast cancer mortality for treatment comparisons that produce a less than 10% (upper panels) or more than 10% (lower
panels) absolute reduction in 5-year local recurrence risk—15-year probabilities
Vertical lines indicate 1 SE above or below the 5, 10, and 15 year percentages.
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comparisons involving more than a 10% reduction in
local recurrence risk, logrank analyses by period of
follow-up provide formal conﬁrmation that the main
reduction in local recurrence occurs during just the ﬁrst
few years. By contrast, for breast cancer mortality there
is no material effect during years 0–2. Subsequently,
however, there are highly signiﬁcant reductions in
breast cancer mortality: 2p0·00001 during each of the
time periods 3–4 years and 5–9 years, and 2p=0·0003
during the time period 10–14 years after randomisation.
After year 15, however, there is no evidence of any
further gain (or loss of the earlier gain) in breast cancer
mortality (webﬁgure 6c). Among those of the 25 000
women who survived to year 15, the ratio, treatment
versus control, of the annual breast cancer mortality rates
in subsequent years was 1·03, SE 0·08. 
Tests of heterogeneity
For each of the three categories of treatment comparison
in table 2, webﬁgure 4 shows the breast cancer mortality
ratios (treatment versus control) separately during the
ﬁrst 5 years after randomisation and in later years, giving
a total of six mortality ratios. For none of these six
mortality ratios is there any signiﬁcant heterogeneity
between the contributions to it from different types of
treatment comparison (webﬁgure 5). Moreover, the sum
of the six heterogeneity test statistics (242=41·2, p=0·5)
provides no signiﬁcant evidence of heterogeneity
between the proportional effects on breast cancer
mortality of local treatments that have similar absolute
effects on local recurrence risks. Such overall tests of
heterogeneity with many degrees of freedom are,
however, not very sensitive to any real heterogeneity that
might exist. A more relevant observation is that in 3 quite
different circumstances the avoidance of local recurrence
(mainly during the ﬁrst 5 years) appeared to be of
comparable relevance to breast cancer mortality (mainly
after the ﬁrst 5 years): (i) in the trials of post-BCS radio-
therapy; (ii) in those of post-mastectomy radiotherapy; and
(iii) in the aggregated results from the trials of breast
conservation or axillary conservation without effective
radiotherapy to the conserved tissue (total logrank O–E
–28·9 [15·75·18·1] with variance 145·2, breast cancer
mortality ratio 0·82, SE 0·08, 2p=0·02; webﬁgure 5).
Subgroup analyses
Analyses of selected treatment comparisons in
subgroups of age and of tumour characteristics (grade,
size, ER status, and amount of nodal involvement, where
available) are given in webﬁgure 6. Any apparent
differences or similarities between the subgroup-speciﬁc
treatment effects are likely to be much more trustworthy
for local recurrence than for breast cancer mortality,
because differences in local treatment can have such
large effects on local recurrence rates. For women with
node-negative disease in the trials of radiotherapy after
BCS (webﬁgure 6a), and for women with node-positive
disease in the trials of radiotherapy after mastectomy and
axillary clearance (webﬁgure 6b), radiotherapy produced
similar proportional reductions in local recurrence risk,
irrespective of age, tumour grade, tumour size, ER status,
or amount of nodal involvement. Consequently, within
each subgroup the absolute beneﬁt produced by
radiotherapy was determined principally by the
magnitude of the local recurrence risk in unirradiated
women. 
Age
Table 3 gives 5-year local recurrence risks for various
subgroups in the trials of radiotherapy after BCS (generally
with axillary clearance) in node-negative disease and in the
trials of radiotherapy after mastectomy and axillary
clearance in node-positive disease. In the former, most
local recurrences are in the conserved breast, and the 
5-year risk of such recurrence in the breast is known to be
about twice as great in younger as in older women.22–25
Hence, the absolute effects of post-BCS radiotherapy on
local recurrence (mainly in the conserved breast) were
greater in younger than in older women (5-year risk
reductions of 22%, 16%, 12%, and 11% for those aged
50, 50–59, 60–69, and 	70 years respectively; test for
trend in absolute beneﬁts 2p=0·00002). By contrast, there
was no trend with age in the 5-year risks of local
recurrence (mainly in the chest wall or lymph nodes)
among women with mastectomy, axillary clearance, and
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5-year local recurrence risk (%) in trials of:
(a) RT after BCS (b)  RT after mastectomy and AC
(node-negative) (node-positive)
RT versus Absolute RT versus Absolute 
control reduction (SE) control reduction (SE)
Age (years)
50 11 vs 33 22 (2) 6 vs 23 17 (1)
50–59 7 vs 23 16 (2) 6 vs 24 18 (2)
60–69 4 vs 16 12 (1) 5 vs 23 18 (2)
70 3 vs 13 11 (2) .. ..
Tumour grade
Well differentiated 4 vs 14 10 (2) 4 vs 22 18 (3)
Moderately differentiated 9 vs 26 17 (2) 4 vs 30 26 (2) 
Poorly differentiated 12 vs 34 22 (3) 6 vs 40 34 (4) 
Tumour size (T category)
1–20 mm (T1) 5 vs 20 15 (1) 5 vs 22 17 (2) 
21–50 mm (T2) 14 vs 35 21 (3) 6 vs 30 24 (2) 
50 mm (T3 or T4*) .. .. 8 vs 36 28 (4) 
ER status
ER-poor 12 vs 30 18 (3) 8 vs 28 20 (2) 
ER-positive 6 vs 25 19 (2) 6 vs 24 18 (2) 
Number of involved nodes
1–3 .. .. 4 vs 16 12 (2) 
4 .. .. 12 vs 26 14 (2) 
All women 7 vs 23 16 (1) 6 vs 23 17 (1) 
See webﬁgures 6a and 6b for more details on characteristics, including separate results for those in whom the relevant
characteristic is not known. *T4=tumour of any size with direct extension to skin or chest wall.
Table 3: Effects of age and tumour characteristics on 5-year risks of local recurrence in trials of
radiotherapy (RT) (a) after BCS in women with node-negative disease and (b) after mastectomy and
axillary clearance (AC) in women with node-positive disease
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node-positive disease. Hence, the absolute effects of post-
mastectomy radiotherapy on the risk of such local
recurrence were also approximately independent of age
(local recurrence reductions of 17%, 18%, and 18% for
women aged 50, 50–59, and 60–69 years respectively;
there were few older women in these trials).
Tumour characteristics
In both types of trial, the 5-year local recurrence risk
without radiotherapy was higher, and the absolute
reduction in this risk from radiotherapy was
correspondingly greater, in women with tumours that
were large or with direct extension to the skin or chest
wall (T2/T3/T4 tumours) or poorly differentiated, but
there was little relevance of ER status to these risks. For
women with mastectomy, axillary clearance, and node-
positive disease, the number of involved nodes (1–3 or
4) was unavailable for more than half the women
(webﬁgure 6b). Where it was available, the 5-year local
recurrence risks, irradiated versus control, were 4%
versus 16% for women with one to three involved nodes
(reduction 12%, SE 2) and 12% versus 26% for women
with four or more involved nodes (reduction 14%, SE 2;
table 3). The 15-year local recurrence reductions differed
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Site of cancer or cause of death, and 3-digit ICD-9 code(s) Events Logrank O–E* Variance of (O–E) Ratio of rates† 2p
Incidence of contralateral breast cancer
By years since randomisation (and, for cases, mean year of randomisation)
0–4 (1980) 673 1·3 161·1 1·01 (0·08) 0·9
5–14 (1980) 627 53·5 150·2 1·43 (0·10) 0·00001
15 (1975) 151 2·1 33·4 1·06 (0·18) 0·7
By age at randomisation
50 years 600 11·7 143·0 1·09 (0·09) 0·3
50 years 851 45·1 201·3 1·25 (0·08) 0·002
By use of systemic therapy
With chemotherapy or tamoxifen 649 21·7 158·0 1·15 (0·09) 0·08
Without chemotherapy or tamoxifen 802 35·1 186·4 1·21 (0·08) 0·01
Total contralateral breast cancer 1451 56·9 344·4 1·18 (0·06) 0·002
Incidence of other speciﬁed cancers‡
Lung cancer (162) 215 24·3 51·1 1·61 (0·18) 0·0007
Oesophagus cancer (150) 31 5·4 7·5 2·06 (0·53) 0·05
Leukaemia (204–208) 59 7·5 13·9 1·71 (0·36) 0·04
Soft-tissue sarcoma (158, 171) 26 5·4 6·4 2·34 (0·62) 0·03
Thyroid cancer 26 2·3 6·2 0·69 (0·34) 0·4
Bone cancer 28 1·7 6·9 1·28 (0·43) 0·5
Other speciﬁed malignant disease 966 16·4 220·7 1·08 (0·07) 0·3
Total other speciﬁed cancers 1351 58·4 312·7 1·20 (0·06) 0·001 
Mortality before recurrence, from causes other than breast cancer
By cause
Circulatory disease 1510 77·6 345·4 1·25 (0·06) 0·00003
Heart disease, etc§ 1106 60·7 252·7 1·27 (0·07) 0·0001
Stroke 345 9·1 80·9 1·12 (0·12) 0·3
Pulmonary embolism 59 7·8 11·8 1·94 (0·41) 0·02
Other speciﬁed cause 1455 6·4 335·8 1·02 (0·06) 0·7
Lung cancer 156 21·7 37·5 1·78 (0·22) 0·0004
Oesophagus cancer 23 4·9 5·6 2·40 (0·68) 0·04
Leukaemia 31 2·4 7·0 1·40 (0·45) 0·4
Soft-tissue sarcoma 7 1·3 1·7 2·13 (1·14) 0·3
Respiratory disease (460–519, 786) 241 1·0 55·5 0·98 (0·13) 0·9
Other known cause 997 22·9 228·5 0·90 (0·06) 0·1
Unspeciﬁed cause, not breast cancer 701 7·8 159·4 1·05 (0·08) 0·5
By years since randomisation (and, for deaths, mean year of randomisation)
0–4 (1976 ) 756 7·4 176·4 1·04 (0·08) 0·6
5–14 (1975) 1513 37·7 348·4 1·11 (0·06) 0·05
15 (1970) 1397 46·9 304·8 1·17 (0·06) 0·01
By age at randomisation
50 years 554 27·4 129·6 1·24 (0·10) 0·02
50 years 3112 64·4 699·8 1·10 (0·04) 0·02
Total non-breast-cancer deaths¶ 3666 91·8 829·4 1·12 (0·04) 0·001
O–E=observed–expected. *Approximate excess number of events in radiotherapy group is 2(O–E). †Ratio of annual event rates (SE), irradiated versus unirradiated, estimated from O–E,
and its variance V as exp([O–E]/V).20 ‡Primary cancers of all speciﬁed sites (140–194, 200–208) except non-melanoma skin (173) and breast. Includes radiotherapy versus not: 3 versus
2 thyroid cancer (193), 1 versus 0 bone cancer (170). §All circulatory (390–459, 785, 798) except stroke (430–438) and pulmonary embolism (415, 451, 453, 673). ¶Analyses in table
(and in corresponding webﬁgure 7) stratiﬁed by only two groups of age; had they been stratiﬁed by ﬁve age groups, as in main analyses, and the node-negative patients in the
80Y Edinburgh trial appropriately removed (see footnotes added in proof to webtables 2 and 3), the mortality results would have changed only very slightly (eg, for total non-breast-
cancer deaths the logrank O–E would have been 93·4 with variance 789·2, rate ratio 1·126, SE 0·04, 2p=0·0009).
Table 4: Effect of radiotherapy on incidence of second cancers before recurrence of breast cancer, and on mortality from causes other than breast cancer
(23 500 women in 46 trials of adding radiotherapy, and 9300 in 17 trials of radiotherapy vs more surgery)
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more substantially, however, and were 14% and 20% for
women with one to three and for those with four or more
involved nodes, respectively (webﬁgures 2d and 2e).
Systemic therapy
In trials of systemic therapy,20 5 years of tamoxifen
reduced the local recurrence rate by about one half in
women with ER-positive disease (local recurrence rate
ratio 0·47, SE 0·08) and, irrespective of ER status,
polychemotherapy reduced it by about one third (ratios
0·63, SE 0·08, and 0·70, SE 0·05, for women aged
50 and 50–69 years, respectively); webﬁgures 9R, 4aR,
4bR in the recent EBCTCG report20 on systemic therapy. 
The local treatment comparisons that produced more
than a 10% absolute reduction in 5-year local recurrence
risk were, however, effective in the presence or in the
absence of systemic therapy (ie, of chemotherapy or
tamoxifen [or both] to both trial groups, or to neither).
Among the women who received systemic therapy, the
mean absolute reduction in 5-year local recurrence risk
was 20% (8% vs 28%, webﬁgure 6c), and the 15-year
reduction in breast cancer mortality was 5·9% (SE 1·2;
49·1% vs 55·1%: 2p0·00001). Thus, better local treat-
ment adds to the effects of systemic therapy on local
recurrence and on breast cancer mortality. 
Four-to-one ratio of absolute effects
Although in the present analyses subgroup-speciﬁc
results derived for local recurrence might well be fairly
reliable (as the effects of local treatment on local
recurrence can be so extreme), subgroup-speciﬁc results
for breast cancer mortality might well not be. Hence,
unduly selective emphasis on particularly favourable or
unfavourable mortality results from particular subgroups
or particular trials, or even from particular types of
treatment comparison, could give rise to misleading
over-estimation or under-estimation of the real relevance
of local disease control to long-term breast cancer
mortality. Instead, the most reliable estimate of the
effect on breast cancer mortality of a particular local
treatment comparison in particular subgroups of
women might come not from the apparent results for
breast cancer mortality in those subgroups, but from
estimating the effect of that treatment comparison on
local recurrence risk in those subgroups, and then
applying the general ﬁnding that a 20% absolute
reduction in 5-year local recurrence risk leads to about a
5% absolute reduction in 15-year breast cancer mortality
(ie, a four-to-one ratio of absolute effects).
Diseases other than the original breast cancer
Table 4 shows the incidence of second cancers and of
mortality from causes other than breast cancer in all the
trials in table 1 that tested radiotherapy (ie, all trials of
radiotherapy vs not [with the same surgery] and all trials
of more surgery vs radiotherapy [with active and control
reversed]). There was an excess cancer incidence among
women allocated radiotherapy that mainly involved
contralateral breast cancer (2p=0·002) and lung cancer
(2p=0·0007), and there was an excess mortality from
causes other than breast cancer that mainly involved
heart disease (2p=0·0001) and lung cancer (2p=0·0004).
Based on much smaller numbers, there was also a
moderately signiﬁcant excess  mortality from pulmonary
embolism and excess incidence of oesophagus cancer,
leukaemia and soft tissue sarcoma. 
The effects of these radiotherapy regimens on
contralateral breast cancer and on mortality from causes
other than breast cancer are plotted against time since
randomisation in webﬁgure 7. The averaged effects on
15-year outcome are not large (9·3% vs 7·5% for
contralateral breast cancer, 15·9% vs 14·6% for non-
breast-cancer mortality), but they may well vary
substantially from one regimen to another, and the
absolute 15-year mortality differences could also depend
strongly on tumour laterality (which can affect cardiac
radiation dose), smoking habits (which affect both
vascular and lung cancer risks), other vascular risk
factors, and, particularly, on age.
The excess of contralateral breast cancer with radio-
therapy appears mainly during the period 5–14 years
after randomisation (table 4, webﬁgure 7) and is
signiﬁcant even among women aged 50 years or older
when randomised (table 4). When the excess mortality
from causes other than breast cancer is subdivided by
time since randomisation, the proportional excess again
appears to be less during the ﬁrst 5 years than in
subsequent years, but it is separately signiﬁcant for the
periods 5–14 years and 15 years or more after
randomisation. The mean dates of randomisation for
those who died 5–14 years and 15 years or more after
randomisation were, however, 1975 and 1970,
respectively, and the radiotherapy regimens of the early
1970s may well have involved greater hazards than many
current regimens. The excess mortality from causes
other than breast cancer is signiﬁcant both for women
younger than 50 years of age and for women older than
50 years of age when randomised (2p=0·02 for both), but
the CIs for the age-speciﬁc risks are wide. The numbers
are not sufﬁcient for the main hazards (contralateral
breast cancer, lung cancer, or heart disease) to be reliably
subdivided by both follow-up duration and age.
Results of similar analyses of the trials of more versus
less surgery indicate no signiﬁcant effect of more
surgery on non-breast-cancer mortality (mortality ratio
1·11, SE 0·09).
Overall mortality in radiotherapy trials
Figure 6 compares, for the two main radiotherapy
analyses, the effects on breast cancer mortality with the
effects on overall mortality. In the post-BCS radiotherapy
trials the absolute reduction in 15-year overall mortality
is about as large as that in 15-year breast cancer
mortality. For these post-BCS trials there is as yet,
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however, little follow-up beyond year 15—indeed, many
women have not yet been followed to year 15. In the
trials of radiotherapy after mastectomy and axillary
clearance in node-positive disease, the reduction in 15-
year all-cause mortality is 4·4% (SE 1·2, 64·2% vs
59·8%, 2p=0·0009). This is less than the 5·4%
reduction in 15-year breast cancer mortality. At 20 years,
the reduction in breast cancer mortality remains
unchanged at 5·4% (66·4% vs 61·0%), while that for all-
cause mortality, although still signiﬁcant, is only 3·5%
(72·3% vs 68·8%), indicating a continuing excess of
non-breast-cancer mortality long after treatment with
the older radiotherapy regimens.
Discussion
Main ﬁndings
About three-quarters of the local recurrence risk (and
more than three-quarters of any treatment effects on
local recurrence) occurred during the ﬁrst 5 years after
randomisation. By contrast, more than half the 15-year
breast cancer mortality (and much more than half of any
such treatment effects on breast cancer mortality)
occurred after the ﬁrst 5 years. Some local treatment
comparisons (eg, axillary clearance vs effective axillary
radiotherapy; mastectomy vs BCS plus effective
radiotherapy; post-mastectomy radiotherapy in node-
negative disease) involved little (10%) absolute
difference in the 5-year risk of local recurrence and, in
aggregate, these comparisons also involved little
difference in 15-year breast cancer mortality (ﬁgure 5,
upper panel). 
Local recurrence and breast cancer mortality
The other local treatment comparisons are those that
involved absolute differences of more than 10% in the 
5-year risk of local recurrence (eg, post-BCS radiotherapy,
mainly to the conserved breast; post-mastectomy
radiotherapy in node-positive disease; conservation of the
breast or axilla without effective radiotherapy to the
conserved tissue). In the aggregate of all such compar-
isons, involving a total of 25 000 women, the 5-year local
recurrence risks were 7% active versus 26% control
(reduction 19%) and the 15-year breast cancer mortality
risks were 44·6% versus 49·5% (reduction 5·0% SE 0·8,
2p0·00001). Treatment comparisons that produced
similar-sized effects on local recurrence tended to
produce similar-sized effects on breast cancer mortality
(webﬁgure 5). In particular, both for the 7300 women in
trials of post-BCS radiotherapy (mostly with axillary
clearance and pathologically node-negative disease) and
for the 8500 women in trials of post-mastectomy
radiotherapy after axillary clearance in node-positive
disease, the absolute reductions in 5-year local
recurrence and in 15-year breast cancer mortality were
similar in magnitude to those in the aggregated results
in all 25 000 women, and were highly signiﬁcant. This
ﬁnding indicates that the avoidance of recurrence in a
conserved breast and the avoidance of other local
recurrence (eg, in the chest wall or regional lymph
nodes) are of comparable relevance to 15-year breast
cancer mortality. In these two particular radiotherapy
comparisons, as in the aggregated results, differences in
local treatment that substantially affect locoregional
recurrence would, in the hypothetical absence of other
causes of death, avoid about one breast cancer death over
the next 15 years for every four such recurrences
avoided. Moreover, even when it does not affect survival,
avoiding a local recurrence can be of substantial beneﬁt. 
Non-breast-cancer mortality and overall mortality
The absence of other causes of death is, of course, not a
realistic assumption, particularly for older patients. Even
the general mortality that is not caused by breast cancer or
its treatment makes the 15-year survival gain somewhat
smaller for overall mortality than for breast cancer
mortality (as it reduces, by a similar factor, the proportion
of 15-year survivors in both the treatment group and the
control group). Moreover, most of the substantial
differences in local recurrence in these trials were
produced by radiotherapy, and some of the radiotherapy
regimens, at least in the older trials of post-mastectomy
radiotherapy, appreciably increased mortality more than 5
years later from diseases other than breast cancer, with
most of this excess mortality involving heart disease and
lung cancer. In addition, this overview conﬁrms the
previous evidence26,27 that radiotherapy can increase the
incidence of contralateral breast cancer more than 5 years
later, which would slightly reduce its net beneﬁcial effect
on 15-year breast cancer mortality. (We cannot ascertain
from the present data whether therapeutic doses of
radiation affect the incidence of new ipsilateral breast
cancer in a conserved breast, as new and recurrent
tumours are not separated.) Nevertheless, at least in the
post-BCS radiotherapy trials, and among women with
axillary clearance and node-positive disease in the post-
mastectomy radiotherapy trials, the radiotherapy
regimens that were tested produced moderate but deﬁnite
reductions not only in 15-year breast cancer mortality but
also in 15-year overall mortality (ﬁgure 6).
Further effects after year 15
The evidence as to what will happen after year 15 is still
limited. Thus far, these trials have shown that the
treatments that substantially reduced the 5-year local
recurrence risk moderately reduced 15-year breast cancer
mortality and 15-year overall mortality. They also suggest
that there will be little additional gain or loss after year 15
in breast cancer mortality (ratio, treatment vs control, of
annual breast cancer death rates during the period after
year 15=1·03, SE 0·08: webﬁgure 3b). There is, however,
evidence from the aggregate of all radiotherapy trials of a
somewhat higher death rate during the period after year
15 from causes other than breast cancer (ratio, radio-
therapy vs not, of annual non-breast-cancer death rates
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after year 15=1·17, SE 0·06), but the mean date of
randomisation for those dying in this late period was
1970, and the late hazards could well be substantially
lower for modern radiotherapy regimens than for those
of the 1960s and 1970s.
Breast cancer mortality rates remain substantial
throughout at least the second decade after diagnosis
(and perhaps beyond) as does the incidence of
contralateral breast cancer, while lung cancer and heart
disease rates increase with advancing age. If long-term
follow-up of many of these trials is continued to 20 or
more years, or even to 30 or more years, distinguishing
between different causes of death (and, to the extent
possible, between new and recurrent tumours in a
conserved breast), the ensuing data will clarify substan-
tially the long-term risks and beneﬁts of the post-BCS
radiotherapy regimens in these trials, as three-quarters
of the women were still alive in the present analyses
(table 1). It will also help clarify substantially the beneﬁts
and risks of both the older and the more recent post-
mastectomy radiotherapy regimens in these trials.
Low and high local recurrence risks
Radiotherapy produces its greatest absolute effects on
local recurrence in women who are at greatest risk of
local recurrence (table 3, ﬁgures 2 and 3). For, whether
the underlying risk is low or high, about 70% of it can be
avoided by radiotherapy. In the trials of post-BCS
radiotherapy, the risk of local recurrence among controls
depended strongly on nodal status (5-year risks: 23%
node-negative, 41% node-positive) and, among those
with node-negative disease, young age, poor tumour
differentiation, and large tumour size all indicated a high
local recurrence risk (table 3). The large majority (78%) of
the node-negative tumours in the post-BCS radiotherapy
trials were small (1–20 mm in their longest diameter),
but, even with such small tumours, without radiotherapy
the 5-year risk of local recurrence was 20% (table 3). 
In the trials of radiotherapy after mastectomy and
axillary clearance, the 5-year risk of local recurrence
among the controls depended strongly on the number of
involved nodes, where this information was available
(risks 6%, 16%, and 26% respectively for 0, 1–3, and 	4
involved nodes). Among women with mastectomy,
axillary clearance, and node-negative disease the absolute
reduction in 5-year local recurrence risk after
radiotherapy was only 4% (2% vs 6%), so if one death
from the original breast cancer is avoided for every four
local recurrences avoided, then the expected reduction in
15-year breast cancer mortality after radiotherapy would
be only 1% (less the adverse effects of any increase in
contralateral disease). Relatively few such women were
randomised, however, and among them the apparent
effect of radiotherapy on breast cancer mortality
happened to be slightly unfavourable.
Only where the absolute effects of radiotherapy on
local recurrence are substantial can they be used to help
quantify any proportional relationship between effects
on local control and on breast cancer mortality. Among
all women with mastectomy, axillary clearance, and
node-positive disease, the absolute effects of radio-
therapy on the 5-year local recurrence risk were
substantial (6% vs 23%), particularly if the tumour was
poorly differentiated or large, and breast cancer
mortality was correspondingly reduced. In these post-
mastectomy trials, however, age was of little or no
relevance to local recurrence (mainly in the nodes or
chest wall), even though in the post-BCS trials age was of
substantial relevance to local recurrence (mainly in the
conserved breast): table 3. 
Generalisability of ﬁndings
Changes in practice
There have been, and will continue to be, substantial
changes in the use, or methods, of screening, surgery,
pathology, radiotherapy, and systemic adjuvant therapy
since many of these trials began.28–30 In particular,
tumour sizes are generally smaller, systemic therapy is
more effective, radiotherapy is less likely to be given to
the internal mammary chain of lymph nodes or to a
surgically-cleared axilla, and there has been increasing
recognition of the late side-effects of radiotherapy and of
the need when treating early breast cancer to limit doses
to the heart and lungs. Hence, depending mainly on the
doses to the heart, lungs, and contralateral breast, the
late hazards of current and future radiotherapy regimens
might well be much lower than those of the regimens
studied in the older trials. Moreover, advances in early
diagnosis, surgery, and systemic therapy mean that the
5-year risks of local recurrence might well be much less
than in these trials. Nevertheless, some risk is likely to
remain, since the desire to control local recurrence (after
either BCS or  mastectomy) has to be balanced not only
against the late adverse effects but also against the
cosmetic and functional effects of excessive local
treatment. 
Prediction of absolute risks and beneﬁts
Prediction from these trials of the long-term risks of
current radiotherapy regimens will depend on approxi-
mate comparison of current and previous radiation
doses to the heart, lungs, etc, while prediction of the
eventual effects on breast cancer mortality will depend
on what the local recurrence risks would currently be
without radiotherapy.
The absolute risks of local recurrence in these trials
and the absolute beneﬁts and hazards of radiotherapy in
these trials cannot be generalised because of the
continuing changes in practice since the trials began.
Nevertheless, the quantitative relationship in these trials
between local disease control and 15-year breast cancer
mortality should still be relevant to current and future
treatment decisions. Where it is possible to estimate the
absolute risk of a particular type of local recurrence after
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a particular type of surgery, it is also possible to estimate
the absolute reduction in this risk that effective
radiotherapy would achieve (as radiotherapy avoids
about 70% of the risk of recurrence in the irradiated
sites) or that would have been avoided by more extensive
surgery (as surgery eliminates the possibility of
recurrence in the excised tissue). From the absolute
reduction in local recurrence the absolute reduction in
breast cancer mortality can be inferred. 
For example, if additional local treatment led to an
estimated reduction in the 5-year local recurrence risk
of, say, about 12% then, from the general four-to-one
relationship between effects on local recurrence and on
breast cancer mortality, it could reasonably reliably be
inferred that the 15-year reduction in breast cancer
mortality would be about 3%, even though directly
randomised proof of such a small mortality difference
would be difﬁcult to obtain. 
Combination of effects of local and systemic therapy
Likewise, as the risk of recurrence in a conserved breast
is about twice as great in younger as in older women, it
could reasonably reliably be inferred that radiotherapy to
a conserved breast (or, in the absence of radiotherapy,
mastectomy rather than BCS) would have a correspond-
ingly greater effect on breast cancer mortality in younger
than in older women, even though the age-speciﬁc
subgroup analyses of mortality have wide conﬁdence
intervals (webﬁgure 6a). Furthermore, avoidance of
death from breast cancer gains more additional years of
life expectancy for younger than for older women. 
Systemic therapy can approximately halve the 5-year
risks of both local and distant recurrence.20 In the
absence of radiotherapy, the risk of local recurrence,
although reduced by surgery and systemic therapy, may
still be substantial.  If it is, then addition of radiotherapy
(or in some cases more extensive surgery) would further
reduce it by a substantial amount and thereby further
reduce 15-year breast cancer mortality by a moderate
amount.10–12,31,32 Indeed, webﬁgure 6c suggests that the
relationship between local control and breast cancer
mortality is much the same with or without systemic
therapy. This conclusion may be of general validity, even
though it is based on the methods of local control and
types of systemic therapy studied in these particular
trials. If so, the moderate differences in 15-year breast
cancer mortality produced by better local control can be
combined with the moderate differences produced by
chemotherapy and hormonal therapy (and, probably, by
newer systemic therapies), yielding in total quite
substantial effects on 15-year breast cancer mortality.
Hence, although for the addition of radiotherapy (or for
other ways of improving local control) the effects on
breast cancer mortality are only moderate, several such
moderate reductions in mortality (from earlier diagnosis,
from improvements in local control, from the introduc-
tion of systemic therapy, and from progressive changes
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in its efﬁcacy) may, in combination, approximately halve
a middle-aged patient’s 15-year risk of death from breast
cancer.  In some countries the introduction of several
such improvements in diagnosis or treatment has, in
aggregate, already led to substantial reductions since 1990
in the national breast cancer mortality rates in middle
age.20
Conclusion
The main purpose of the present overview is to help
predict the effects of different treatment strategies on
long-term survival. It makes no treatment recommenda-
tions, nor does it assess the costs or the functional,
cosmetic, or psychological effects of different treatments.
In early breast cancer, local treatments that substantially
improve local control have little effect on breast cancer
mortality during the ﬁrst few years, but have deﬁnite,
although moderate, effects by 15 years, and avoidance of
local recurrence in a conserved breast and elsewhere are
of comparable relevance to 15-year breast cancer
mortality. These trials of radiotherapy and of the extent
of surgery show that, in the hypothetical absence of other
causes of death, about one breast cancer death over the
next 15 years would be avoided for every four local
recurrences avoided. Although the management of early
breast cancer continues to change, it is reasonable to
assume that this approximate four-to-one relationship
will continue to apply and will still be of relevance to
future treatment choices.
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